1 Min Read
In many ways, 2026 is the year of peptides. Injectable research peptides, like BPC-157 and TB-500, exploded in popularity last year, going from niche biohacker protocol to mainstream curiosity. Now, an influx of new wellness businesses have sprung up to handle the demand just as the FDA is loosening regulations to further proliferate their availability. This coincides with the democratization of GLP-1 peptides. After three years of short supply, GLP-1s like Ozempic are now widely available and, as of this month, three GLP-1 pills have been released, including the Wegovy Pill.Continue reading this article on glossy.co. Sign up for Glossy newsletters to get the latest on the business of beauty, fashion and pop culture.
Work & Theory on April 20, 2026
Uncategorized